The Eighth Edition Lung Cancer Stage Classification

Detterbeck, Frank C.; Boffa, Daniel J.; Kim, Anthony W.; Tanoue, L.T.

doi:10.1016/j.chest.2016.10.010

Cited by 1,293 publications

(993 citation statements)

References 17 publications

Supporting

Mentioning

971

Contrasting

Unclassified

Order By: Relevance

“…Overall, 57% of patients (16 cases) were male, and the majority of patients (24 cases) did not have a history of smoking. The majority of patients (89.3%, 25/28) were diagnosed in advanced (tumor-node-metastasis III and IV) stages (19).…”

Section: Resultsmentioning

confidence: 99%

Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases

Chen

Yang³

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Lung cancer is the most common type of malignancy to metastasize to the brain, with the median survival time of patients being 6-11 months. In the present study, the aim was to compare the actionable gene mutation profiles of primary lung adenocarcinoma (LC) samples and LC brain metastasis (LCBM) samples through targeted sequencing. Next generation sequencing (NGS) of 13 formalin-fixed, paraffin-embedded LC samples and 15 LCBM samples was performed using a customized OncoAim™ cancer panel and OncoAim™ RNA fusion panel on the MiSeq platform. The OncoAim™ cancer panel pipeline and OncoAim™ RNA fusion panel pipeline were used for bioinformatic analysis. Together, 43 variants were observed in 7 genes from the 28 cancer samples. The mutated genes of LCBM were tumor protein (TP)53, epidermal growth factor receptor (EGFR), catenin β1, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α, mothers against decapentaplegic homolog 4, Kirsten rat sarcoma viral oncogene homolog (KRAS) and proto-oncogene B-Raf, which were exhibited in 10/15 (66.7%), 6/15 (40.0%), 3/15 (20.0%), 2/15 (13.3%), 2/15 (13.3%), 1/15 (6.7%) and 1/15 (6.7%) of samples, respectively. The mutated genes of LC were TP53, EGFR and KRAS, which were exhibited in 11/13 (84.6%), 5/13 (38.5%) and 2/13 (18.2%) of samples, respectively. echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase rearrangements were present in 1 LCBM sample. For 2 LC samples and 1 LCBM sample, no genetic alterations were observed. The NGS data also revealed a novel 4-codon deletion of TP53 (p.V166_H169del) and a novel TP53 splice site mutation (7577157-63del TACTCAG). Further potentially actionable mutations were detected in LCBM, indicating a high degree of genetic heterogeneity between the LC and LCBM samples that were analyzed. The present study demonstrated that NGS provides an improved approach for the discovery of potentially actionable mutations and the understanding of the mechanisms underlying tumor progression and evolution.

show abstract

Section: Resultsmentioning

confidence: 99%

Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases

Chen

Yang³

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…In comparison with the patients in the control groups, patients in the experimental groups spent fewer days in As guideline compliance is strongly associated with survival, other bodies, apart from national societies, should be involved to improve adherence. 20 .…”

Section: Barcelona Respiratory Networkmentioning

confidence: 99%

Lung Cancer Management: where are we in 2017?

Scagliotti¹,

Bironzo²,

Rosell³

2017

BRN

View full text Add to dashboard Cite

“…Survival in lung cancer is dependent on histologic subtype, anatomic tumor extension revealed by the TNM stage, gender, age, performance status, comorbidities, genomics, environment and treatment-related factors [4].…”

mentioning

confidence: 99%

“…The 8th edition of the Union for International Cancer Control TNM Classification of Malignant Tumors was recently updated. Five years of survival for extended tumor or IV-stage NSCLC disease is limited to 5-13% [4,5].…”

mentioning

confidence: 99%

“…Therapy in lung cancer is established according to histological type [non-small cell lung cancer (NSCLC) represents 80 to 85% of all lung cancers], TNM stage and, lately, by the presence/absence of driver mutations, making possible new personalized therapy, capable to predict a better patient's therapeutic response and to aim mostly malignant cells with minor side effects [4,6]. As the first presentation of a patient in a Romanian Pneumology department, specialists need to be aware of the real possibilities of improving prognosis by earlier detection of molecular markers.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Intake of Molecular Markers in Lung Cancer The Pulmonologist Point Of View

Danteş

Tofolean

Fildan

et al. 2017

ARS Medica Tomitana

View full text Add to dashboard Cite

Lung cancer remains one of the most frequent pathologies in Pulmonology Departments. Tumor extension, histopathological types, and treatment influence the prognosis and survival in lung cancer. Five years survival dramatically decreases for the 4th-stage of the disease. Non-small cell lung cancer (NSCLC) represents the vast majority of lung cancers. In the last decades, important findings have been made on identifying standardized molecular biomarkers that control tumor growth in lung adenocarcinoma. The discovery of new drugs led to the increased survival, even in extensive forms of the disease. The greatest advances could be obtained by targeting EGFR genetic mutations or EML4-ALK translocate in patients diagnosed with adenocarcinoma lung cancer.

show abstract

The Eighth Edition Lung Cancer Stage Classification

Cited by 1,293 publications

References 17 publications

Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases

Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases

Lung Cancer Management: where are we in 2017?

Prognostic Intake of Molecular Markers in Lung Cancer The Pulmonologist Point Of View

Contact Info

Product

Resources

About